Welcome to IthaMaps

IthaMaps is a global epidemiology database of heamoglobinopathies, illustrating published data on a dynamic global to regional map. Country-specific information on haemoglobinopathy-related policies, prevalence, incidence and overall disease burden is given, including relative allele frequencies of specific globin mutations in each country and/or region, dynamically linked to corresponding IthaGenes entries.

IthaMaps content was supported by partnership with the HVP Global Globin 2020 Challenge

Search

Search Country: OR Search for:  Show organisations

  General information for Lebanon


Lebanon
Continent: Asia
Capital: Beirut
Population: 4125247
Area (in sq km): 10400.0

Haemoglobinopathy-specific healthcare policy information for Lebanon

Healthcare policyComment/InfoReference
Prevention programme: Yes (National)Premarital screening for carriers is mandated by law; since 1994.[PMID: 25030035]
SCD newborn screening: NoPilot haemoglobinopathy NBS program; SCD screening status unknown. From PMID: 19606054, SS-Hb is included in private MS/MS-based programs.[PMID: 33073010]
Prenatal screening: Yes (National)PND since 2000; PGD since 2010.[PMID: 25030035]
Dedicated treatment centres: Yes (National)[PMID: 25030035]
Blood transfusion availability: Yes (National)From: PGPR, Global Sickle Cell Disease Network.
MRI facilities: Yes (National)From: PGPR, Global Sickle Cell Disease Network.
Genetic counselling: Yes (National)Premarital screening results are not always given to the couple by a trained medical professional who can explain the implications.[PMID: 34433959]

  Prevalence and incidence of major haemoglobinopathies in Lebanon

HaemoglobinopathyComment/InfoReference
Prevalence of β-thalassaemia carriers: 3.5 % of the population[PMID: 24672827]
Prevalence of sickle cell disease carriers: 2.1 % of the populationThe rate spikes to 3.5% in the north, in Palestinian refugee camps and in the south.[PMID: 34433959]
Prevalence of α-thalassaemia carriers: 1 % of the populationLess than 1%.[PMID: 23224852]
Prevalence of Hb C carriers: 0 % of the population[PMID: 26633548]
Expected incidence of β-thalassaemia: 19 expected affected births/year[PMID: 24672827]
Expected incidence of sickle cell disease: 28 expected affected births/year[PMID: 24672827]
Incidence of sickle cell disease: 251 affected births/yearMedian value estimated using statistical model and demographic data.[PMID: 23103089]
Known β-thalassaemia patients: 678 patients[PMID: 24672827]
Known sickle cell disease patients: 387 patients[PMID: 24672827]

  Global Burden of Disease data for Lebanon

  Migration data for Lebanon

Mutation frequencies in Lebanon

 Overview (most frequent mutations with their observed average values and range)

 β-locus

IVS I-110 G>A: 33.49 % (11.9 % – 51.4 %)IVS I-1 G>A: 14.88 % (4.9 % – 24.6 %)
IVS I-6 (T>C): 13.32 % (5.5 % – 21.1 %)CD 29 (C>T) or IVS I (-3) GGC>GGT (Gly>Gly): 10.88 % (3.6 % – 32.2 %)

 Detailed mutation frequencies

Entry IDLocusRegionEthnic GroupPopulation TypeSample SizeStudy period (from)Study period (to)ReferenceComments
23390β-locusCountry-wideLebaneseCarriers11019979358011Frequencies are shown for beta-globin gene mutations. Mutations CD 39 C>T, CD 8/9 (+G), CD 30 G>A, IVS I-116 T>G, CD 6 (-A), CD 41/42 (-CTTT), -101 C>T, and 44-bp deletion (from cd 24 to IVS1-26) were not detected in this sample.
23391β-locusCountry-wideLebaneseCarriers and Patients277200011186256Frequencies are shown for beta-globin gene mutations and were reported both in carriers (16.2%) and patients (83.8%).
23392β-locusCountry-wideMulti-EthnicCarriers and Patients2502012201833947296Frequencies are shown for beta-globin gene mutations and were reported both in carriers (36%) and patients (64%). Study subjects were recruited at the American University of Beirut Medical Center (AUBMC), Beirut, and were ethnic Lebanese (74%), Iraqi (15%) and Syrian (11%).
23393β-locusCountry-wideLebaneseCarriers and Patients520200515638828Frequencies are shown for beta-globin gene mutations and were reported both in carriers (40.5%) and patients (59.5%). Study subjects were recruited at the Chronic Care Center in Lebanon from across five geographic regions (Bekaa, South Lebanon, Beirut, North Lebanon and Mount Lebanon).
23394β-locusBekaaLebaneseCarriers and Patients118200515638828Frequencies are shown for beta-globin gene mutations. The study sample was acquired from the Chronic Care Center in Lebanon.
23395β-locusSouth LebanonLebaneseCarriers and Patients144200515638828Frequencies are shown for beta-globin gene mutations from patients residing in the South Lebanon and An Nabatiyah regions. Study samples were acquired from the Chronic Care Center in Lebanon.
23396β-locusBeirutLebaneseCarriers and Patients68200515638828Frequencies are shown for beta-globin gene mutations. The study sample was acquired from the Chronic Care Center in Lebanon.
23397β-locusNorth LebanonLebaneseCarriers and Patients114200515638828Frequencies are shown for beta-globin gene mutations. The study sample was acquired from the Chronic Care Center in Lebanon.
23398β-locusMount LebanonLebaneseCarriers and Patients76200515638828Frequencies are shown for beta-globin gene mutations. The study sample was acquired from the Chronic Care Center in Lebanon.

  Organisations in Lebanon

A list of all organisations in Lebanon stored in the ITHANET database is shown below. For more information, click on the corresponding organisation name or visit the detailed ITHANET Organisations page

NameDepartmentOrganisation type
American University of Beirut Medical Center (AUBMC)Department of Internal MedicineResearch Center, Medical Center, Higher Education
Chronic Care Center Medical Center

 Microattributions

No microattibutions were provided for Lebanon. Please contact us, if you are willing to review existing information or provide new data.

To provide new epidemiological information and/or report mistakes, please register/log in first or use the Contact Us form.

Important Note: The relative allele frequencies presented in IthaMaps are not calculated by ITHANET, but they are extracted from the corresponding publications. ITHANET is not responsible for any mistakes in the data. Please use this information with caution! We encourage scientists that have more detailed or updated epidemiological information to contact us.

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaMaps are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.